142 related articles for article (PubMed ID: 38507442)
1. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody.
Masuyuki R; Sato E; Imafuku S
J Dermatol; 2024 Mar; ():. PubMed ID: 38507442
[TBL] [Abstract][Full Text] [Related]
2. A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma.
Tanaka A; Fujimura Y; Fuke S; Izumi K; Ujiie H
J Dermatol; 2023 Sep; 50(9):1199-1202. PubMed ID: 37122191
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
5. IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid.
Sun C; Qian H; Liang G; Xiang R; Zhao C; Li Z; Suo L; Jing K; Wang Y; Zhang H; Li X; Feng S
Eur J Dermatol; 2023 Dec; 33(6):595-603. PubMed ID: 38465539
[TBL] [Abstract][Full Text] [Related]
6. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
7. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
8. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
10. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
11. Nemolizumab for atopic dermatitis.
Labib A; Vander Does A; Yosipovitch G
Drugs Today (Barc); 2022 Apr; 58(4):159-173. PubMed ID: 35412530
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab for bullous pemphigoid with intractable pruritus.
Seidman JS; Eichenfield DZ; Orme CM
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
[TBL] [Abstract][Full Text] [Related]
14. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
16. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
[TBL] [Abstract][Full Text] [Related]
17. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
18. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
Wang SH; Shan Y; Li SZ; Zuo YG
Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
[TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance.
Tukaj S; Bieber K; Prüßmann W; Prüßmann JN; Schmidt E; Zillikens D; Ludwig RJ; Kasperkiewicz M
Arch Dermatol Res; 2023 Dec; 315(10):2921-2926. PubMed ID: 35960354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
